Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

A Phase II Trial Of Eltrombopag For Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia

Nitin Jain, MD, Michael J. Keating, MD, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Charles Koller, MD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, William G. Wierda, MD, PhD

Blood (2013) 122 (21): 4186.

https://doi.org/10.1182/blood.V122.21.4186.4186

Published: 2013

Journal Articles

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Alfonso Quintás-Cardama, M.D., Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Sherry A. Pierce, RN, BS, Moshe Talpaz, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 918.

https://doi.org/10.1182/blood.V120.21.918.918

Published: 2012

Journal Articles

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

Aziz Nazha, Carlos E. Bueso-Ramos, MD, PhD, Stefan Faderl, MD, Elihu H. Estey, MD, Susan M. O'Brien, Michael Farnandez, Martin Nguyen, Charles Koller, MD, Emil Freireich, MD, Miloslav Beran, Sherry Pierce, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2616.

https://doi.org/10.1182/blood.V120.21.2616.2616

Published: 2012

Journal Articles

Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB)

Theresa Liu-Dumlao, MD, Susan O'Brien, MD, Jorge E. Cortes, Deborah A. Thomas, MD, Stefan Faderl, MD, Elias Jabbour, Charles Koller, MD, Rebecca Garris, BSc, Partow Kebriaei, MD, Richard Champlin, MD, Gautam Borthakur, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, Farhad Ravandi, MD

Blood (2011) 118 (21): 2578.

https://doi.org/10.1182/blood.V118.21.2578.2578

Published: 2011

Journal Articles

Outcome of Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy

Hun Ju Lee, MD, Susan O'Brien, MD, Hagop M. Kantarjian, Farhad Ravandi, MD, Stefan Faderl, MD, Charles Koller, MD, Marina Konopleva, M.D., Ph.D., Srdan Verstovsek, MD, PhD, Tapan Kadia, Guillermo Garcia-Manero, Gautam Borthakur, William G. Wierda, MD, PhD, Jan A. Burger, MD, PhD, Deborah A. Thomas, MD, Jorge E. Cortes

Blood (2011) 118 (21): 1518.

https://doi.org/10.1182/blood.V118.21.1518.1518

Published: 2011

Journal Articles

Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Hun Ju Lee, MD, Hagop M. Kantarjian, Deborah A. Thomas, MD, Stefan Faderl, MD, Charles Koller, MD, Alessandra Ferrajoli, MD, Elias Jabbour, Rebecca Garris, BSc, Partow Kebriaei, MD, Richard Champlin, MD, Gautam Borthakur, William G. Wierda, MD, PhD, Jan A. Burger, MD, PhD, Jorge E. Cortes, Susan O'Brien, MD, Farhad Ravandi, MD

Blood (2011) 118 (21): 1512.

https://doi.org/10.1182/blood.V118.21.1512.1512

Published: 2011

Journal Articles

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Elias Jabbour, MD, Charles Koller, MD, Samuel Dara, Rebecca Garris, Partow Kebriaei, MD, Gautam Borthakur, MD, Alessandra Ferrajoli, MD., Susan O'Brien

Blood (2009) 114 (22): 2043.

https://doi.org/10.1182/blood.V114.22.2043.2043

Published: 2009

Journal Articles

Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL).

Fabio P.S. Santos, MD, Susan O'Brien, MD, Deborah A. Thomas, MD, Jorge Cortes, MD, Stefan Faderl, MD, Jeffrey L. Jorgensen, MD, PhD, Rebecca Garris, Charles Koller, MD, Partow Kebriaei, MD, Alessandra Ferrajoli, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD

Blood (2009) 114 (22): 984.

https://doi.org/10.1182/blood.V114.22.984.984

Published: 2009

Journal Articles

Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 836.

https://doi.org/10.1182/blood.V114.22.836.836

Published: 2009

Journal Articles

Clinical Characterization and Proteomic Consequences of Mutated Ras in Acute Myeloid Leukemia.

Tapan Kadia, MD, Steven M. Kornblau, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Guillermo Garcia-Manero, MD, Gautam Borthakur, Charles Koller, MD, Srdan Verstovsek, MD, PhD, Sherry Pierce, RN, Jorge Cortes, MD, Farhad Ravandi, MD

Blood (2009) 114 (22): 330.

https://doi.org/10.1182/blood.V114.22.330.330

Published: 2009

Journal Articles

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

Xavier C. Badoux, MBBS, Michael Keating, MD, Susan O'Brien, MD, Tapan Kadia, MD, Alessandra Ferrajoli, MD., Stefan Faderl, MD, Charles Koller, MD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD, PhD, William G. Wierda, M.D., Ph.D,

Blood (2009) 114 (22): 3431.

https://doi.org/10.1182/blood.V114.22.3431.3431

Published: 2009

Journal Articles

Combination Therapy with Tyrosine Kinase Inhibitors and Agents with Different Mechnisms of Actions Is Effective in a Patient with Chronic Myeloid Leukemia Harboring the T315l BCR - ABL1 Mutation.

Fabio P S Santos, MD, Jorge Cortes, MD, Charles Koller, MD, Elias Jabbour, MD

Blood (2009) 114 (22): 4282.

https://doi.org/10.1182/blood.V114.22.4282.4282

Published: 2009

Journal Articles

Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia.

Sameer A Parikh, MD, Michael Keating, MD, Susan O'Brien, Alessandra Ferrajoli, Stefan Faderl, MD, Charles Koller, MD, Zeev Estrov, Susan Lerner, M.S., RHIA, William G. Wierda, M.D., Ph.D

Blood (2009) 114 (22): 208.

https://doi.org/10.1182/blood.V114.22.208.208

Published: 2009

Journal Articles

Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Farhad Ravandi, MBBS, Deborah Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Samuel Dara, MD, Rebecca Garris, BS, Partow Kebriaei, MD, Gautam Borthakur, MD, William Wierda, MD, PhD, Jan Burger, MD, Jorge Cortes, MD, Susan O’Brien, MD

Blood (2008) 112 (11): 2921.

https://doi.org/10.1182/blood.V112.11.2921.2921

Published: 2008

Journal Articles

CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p.

William G Wierda, MD, PhD, Susan M O’Brien, MD, Stefan H Faderl, MD, Alessandra Ferrajoli, MD, Charles Koller, MD, Zeev Estrov, MD, Jan A Burger, MD, PhD, Susan Lerner, Hagop M. Kantarjian, MD, Michael J Keating, MBBS

Blood (2008) 112 (11): 2095.

https://doi.org/10.1182/blood.V112.11.2095.2095

Published: 2008

Journal Articles

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Apostolia-Maria Tsimberidou, MD, PhD, Hagop Kantarjian, MD, Susan O’Brien, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Daniel Jones, MD, Sherry Pierce, RN, Mark Brandt, BA, Michael Keating, MB, BS, Estey Estey, MD

Blood (2007) 110 (11): 1834.

https://doi.org/10.1182/blood.V110.11.1834.1834

Published: 2007

Journal Articles

Event-Free Survival in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with 2 nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure Is Dependent on the In Vitro Sensitivity of BCR-ABL Kinase Domain (KD) Mutations.

Elias Jabbour, MD, Hagop Kantarjian, MD, Dan Jones, MD, Constantine Tam, MD, Charles Koller, MD, Gautam Borthakur, MD, William Wierda, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 1941.

https://doi.org/10.1182/blood.V110.11.1941.1941

Published: 2007

Journal Articles

Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.

Farhad Ravandi, MD, Stefan Faderl, MD, Deborah Thomas, MD, Jan Burger, MD, Charles Koller, MD, Guillermo Garcia-Manero, MD, Gail Morris, RN, Ritva Torma, RN, Hagop Kantarjian, MD, Jean-Pierre Issa, MD

Blood (2007) 110 (11): 897.

https://doi.org/10.1182/blood.V110.11.897.897

Published: 2007

Journal Articles

Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.

Dushyant Verma, MD, FACP, Deborah Thomas, MD, Susan O’Brien, MD, Stefan Faderl, MD, Charles Koller, MD, Sherry Pierce, RN, Elihu Estey, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD

Blood (2007) 110 (11): 2832.

https://doi.org/10.1182/blood.V110.11.2832.2832

Published: 2007

Journal Articles

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Farhad Ravandi, MD, Deborah Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Devri Brown, Rebecca Garris, Gautam Borthakur, MD, Jan Burger, MD, Partow Kebriaei, MD, Jeffrey Jorgensen, MD, Dan Jones, MD, Jorge Cortes, MD, Susan O’Brien, MD

Blood (2007) 110 (11): 2814.

https://doi.org/10.1182/blood.V110.11.2814.2814

Published: 2007

NARROW

A Phase II Trial Of Eltrombopag For Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB)

Outcome of Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy

Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL).

Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL).

Clinical Characterization and Proteomic Consequences of Mutated Ras in Acute Myeloid Leukemia.

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

Combination Therapy with Tyrosine Kinase Inhibitors and Agents with Different Mechnisms of Actions Is Effective in a Patient with Chronic Myeloid Leukemia Harboring the T315l BCR - ABL1 Mutation.

Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia.

Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p.

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Event-Free Survival in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with 2 nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure Is Dependent on the In Vitro Sensitivity of BCR-ABL Kinase Domain (KD) Mutations.

Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.

Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only